Evidence map›Paper›PMID 31504796›Full record

ArticleNeuro-oncology2019

Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

Francesco Pasqualetti, Giuliana Restante, Alessandra Gonnelli, Eleonora Rofi, Alessandro Molinari, Stefania Crucitta, Fabiola Paiar, Roberta Rudà, Romano Danesi, Riccardo Soffietti and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Francesco PasqualettiRadiation Oncology, Department of Medicine and Oncology, University Hospital, Pisa, Italy.
Giuliana RestanteUnit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandra GonnelliRadiation Oncology, Department of Medicine and Oncology, University Hospital, Pisa, Italy.
Eleonora RofiUnit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Alessandro MolinariRadiation Oncology, Department of Medicine and Oncology, University Hospital, Pisa, Italy.
Stefania CrucittaUnit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Fabiola PaiarRadiation Oncology, Department of Medicine and Oncology, University Hospital, Pisa, Italy.
Roberta RudàDepartment of Neuro-Oncology, University of Turin and City of Health and Science University Hospital, Turin, Italy.
Romano DanesiUnit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Riccardo SoffiettiDepartment of Neuro-Oncology, University of Turin and City of Health and Science University Hospital, Turin, Italy.
Marzia Del ReUnit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MutationAdultAntineoplastic AgentsBrain NeoplasmsExosomesFemaleGangliogliomaHumansImidazolesOximesPrognosisProto-Oncogene Proteins B-rafRNA, NeoplasmAntineoplastic AgentsBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafRNA, Neoplasmbrain tumorscirculating free DNAdabrafenibexosome-derived cancer mRNARAF

Identifiers

PMID31504796
PMCPMC6917399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.